New perspectives for wound healing and the treatment of chronic diseases

"Until now, our understanding of fibroblast diversity has been based primarily on studies in animal models. This new review is the first to compare and integrate extensive human studies that have used modern single-cell technologies. This approach makes it possible to combine findings from different human studies, creating a comprehensive picture of the various origins and functions of human fibroblasts," says Professor Sandra Franz, lead author of the study from the University of Leipzig Medical Center.

This deeper understanding of cellular heterogeneity opens up new avenues for the development of targeted therapies. In the future, it may be possible to specifically address certain fibroblast subtypes -- for example, to promote tissue repair or to inhibit pathological processes such as tumour growth. This is particularly significant for regenerative medicine and the treatment of chronic diseases.

The authors of the study -- Dr Marta Torregrossa, Professor Jan C. Simon, and Professor Sandra Franz (all from the University of Leipzig Medical Center), together with Dr Yuval Rinkevich (Helmholtz Munich) -- are conducting joint research as part of the ZellTWund project. Their aim is to further characterise regeneration-promoting fibroblast subtypes and their roles in health and disease -- thereby paving the way for new therapeutic approaches. Translating these findings into clinical applications remains a key challenge for the coming years, the Leipzig researchers conclude.